\n\n
A new partnership announced on 6 October sees six leading scientific publishers—including Sage, the BMJ group and Wangfang data—provide a Swedish AI firm, Redpine, with access to more than 20 million research articles. The arrangement operates on a novel “pay‑per‑use” model, where the AI startup pays both publishers and authors each time the literature is accessed.
Key developments: the deal unlocks vast, previously paywalled scientific literature for AI agents, allowing them to pull detailed insights rather than mere abstracts. Redpine says this will empower drug‑discovery teams to mine decades of peer‑reviewed studies and enable trial‑design AI to sift through thousands of past trials to pinpoint realistic patient cohorts and endpoints.
Why it matters: providing AI with direct, granular access to primary research accelerates hypothesis generation, data‑driven experiment design, and the translation of findings into therapeutic pipelines. The pay‑per‑use model also creates a revenue stream for publishers and authors, addressing concerns over data commodification while fostering broader AI‑driven innovation.
What to watch next: adoption of similar models by other publishers, the impact on drug‑discovery timelines and success rates, and regulatory scrutiny of AI‑derived conclusions drawn from proprietary scientific literature. [[1]]